Clinical trials: Bleeding Tendency; Due to Coagulation Defect

Acquired Hemophilia A

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

• Completed
• Age: 18 years and older
• Phase 2/3
• Results posted

This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.

Trial name

NCT01178294

Testing

OBI-1

Where

12 sites in United States, Canada and 2 more

Volunteers

29 people

Sponsor

Baxalta now part of Shire